A drug device combination product is composed of any combination of a drug and a device; a biological product and a device; a drug and a biological product; or a drug, device, and a biological product. Under 21 CFR 3.2 (e), a combination product is defined as a product comprised of two or more regulated components (i.e., drug/device, biologic/device, drug/biologic, or drug/device/biologic) that are physically, chemically, or otherwise combined or mixed and produced as a single entity; and, two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products.
The global drug device combination products market segmentation is based on device types (drug eluting stents, coronary stents, peripheral vascular stents, infusion pumps, implantable infusion pumps, ambulatory infusion pumps, photosensitizers, orthopedic combination products, antibiotic bone cement, bone graft implants, wound care combination products, antibiotic wound care products, inhalers, nebulizers, metered dose inhalers, dry powder inhalers, transdermal patches, intraocular implants, drug eluting beads).
The global drug device combination products market report provides market size (Revenue USD Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021). The global drug device combination products market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.